A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 102-109

  Suh, Young Ah ^a   Kim, Jai Hyun ^b   Sung, Myung A ^c   Boo, Hye Jin ^c   Yun, Hye Jeong ^c   Lee, Sun Hye ^a   Lee, Hyo Jong ^d   Min, Hye Young ^c   Suh, Young Ger ^c   Kim, Kyu Won ^c   Lee, Ho Young ^c  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Seoul National University   (South Korea)

^d Inje University   (South Korea)

Author keywords

Apoptosis; Breast cancer; Deguelin; IGFBP 3; IGFR signaling

Indexed keywords

DEGUELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MCF-7 CELLS; MICE; MICE, NUDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOMEDIN; RNA INTERFERENCE; ROTENONE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875254298     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.022     Document Type: Article

References (45)

1. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 2003, 278:30458-30468.
2. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer 2005, 12:721-747.
3. Martin L.A., Farmer I., Johnston S.R., Ali S., Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocrine-Related Cancer 2005, 12(Suppl. 1):S75-84.
4. Chun K.H., Kosmeder J.W., Sun S., Pezzuto J.M., Lotan R., Hong W.K., Lee H.Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. Journal of the National Cancer Institute 2003, 95:291-302.
5. Lee H.Y., Oh S.H., Woo J.K., Kim W.Y., Van Pelt C.S., Price R.E., Cody D., Tran H., Pezzuto J.M., Moriarty R.M., Hong W.K. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. Journal of the National Cancer Institute 2005, 97:1695-1699.
6. Oh S.H., Woo J.K., Yazici Y.D., Myers J.N., Kim W.Y., Jin Q., Hong S.S., Park H.J., Suh Y.G., Kim K.W., Hong W.K., Lee H.Y. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. Journal of the National Cancer Institute 2007, 99:949-961.
7. Kim W.Y., Oh S.H., Woo J.K., Hong W.K., Lee H.Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Research 2009, 69:1624-1632.
8. Yi T., Li H., Wang X., Wu Z. Enhancement radiosensitization of breast cancer cells by deguelin. Cancer Biotherapy and Radiopharmaceuticals 2008, 23:355-362.
9. Jin Q., Feng L., Behrens C., Bekele B.N., Wistuba II, Hong W.K., Lee H.Y. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Research 2007, 67:11630-11639.
10. Hinnis A.R., Luckett J.C., Walker R.A. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. British Journal of Cancer 2007, 96:639-645.
11. Peng X.H., Karna P., O'Regan R.M., Liu X., Naithani R., Moriarty R.M., Wood W.C., Lee H.Y., Yang L. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Molecular Pharmacology 2007, 71:101-111.
12. Gerhauser C., Lee S.K., Kosmeder J.W., Moriarty R.M., Hamel E., Mehta R.G., Moon R.C., Pezzuto J.M. Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Research 1997, 57:3429-3435.
13. Tran J., Rak J., Sheehan C., Saibil S.D., LaCasse E., Korneluk R.G., Kerbel R.S. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochemical and Biophysical Research Communications 1999, 264:781-788.
14. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer 2008, 8:915-928.
15. Probst-Hensch N.M., Yuan J.M., Stanczyk F.Z., Gao Y.T., Ross R.K., Yu M.C. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. British Journal of Cancer 2001, 85:1695-1699.
16. Gross J.M., Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Reviews 2003, 22:327-336.
17. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 2000, 92:1472-1489.
18. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Molecular and Cellular Biology 1997, 17:1595-1606.
19. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer 2002, 2:489-501.
20. Davison Z., de Blacquiere G.E., Westley B.R., May F.E. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011, 13:504-515.
21. Frasca F., Pandini G., Vigneri R., Goldfine I.D. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Disease 2003, 17:73-89.
22. Nickerson T., Huynh H., Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochemical and Biophysical Research Communications 1997, 237:690-693.
23. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:40-50.
24. Murillo G., Peng X., Torres K.E., Mehta R.G. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prevention Research (Phila) 2009, 2:942-950.
25. Ito S., Oyake T., Murai K., Ishida Y. Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Leukemia Research 2010, 34:352-357.
26. Dat N.T., Lee J.H., Lee K., Hong Y.S., Kim Y.H., Lee J.J. Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression. Journal of Natural Products 2008, 71:1696-1700.
27. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology 2008, 8:384-392.
28. Murillo G., Salti G.I., Kosmeder J.W., Pezzuto J.M., Mehta R.G. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. European Journal of Cancer 2002, 38:2446-2454.
29. Genoveva Murillo J.W.K.I., Pezzuto John M., Mehta Rajendra G. Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. International Journal of Cancer 2003, 104:7-11.
30. Jin Q., Menter D.G., Mao L., Hong W.K., Lee H.Y. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 2008, 29:1614-1622.
31. Lee H.Y. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. Biochemical Pharmacology 2004, 68:1119-1124.
32. Oh S.H., Woo J.K., Jin Q., Kang H.J., Jeong J.W., Kim K.W., Hong W.K., Lee H.Y. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. International Journal of Cancer 2008, 122:5-14.
33. Thamilselvan V., Menon M., Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 beta/beta-catenin pathway. International Journal of Cancer 2011, 129:2916-2927.
34. Chang Y.S., Wang L., Suh Y.A., Mao L., Karpen S.J., Khuri F.R., Hong W.K., Lee H.Y. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 2004, 23:6569-6580.
35. Chang Y.S., Kong G., Sun S., Liu D., El-Naggar A.K., Khuri F.R., Hong W.K., Lee H.Y. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2002, 8:3796-3802.
36. Lee H.Y., Chun K.H., Liu B., Wiehle S.A., Cristiano R.J., Hong W.K., Cohen P., Kurie J.M. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Research 2002, 62:3530-3537.
37. Papadimitrakopoulou V.A., Brown E.N., Liu D.D., El-Naggar A.K., Jack Lee J., Hong W.K., Lee H.Y. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Letters 2006, 239:136-143.
38. Oh S.H., Jin Q., Kim E.S., Khuri F.R., Lee H.Y. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:1581-1589.
39. Jogie-Brahim S., Feldman D., Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocrine Reviews 2009, 30:417-437.
40. Pratt S.E., Pollak M.N. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochemical and Biophysical Research Communications 1994, 198:292-297.
41. Sheikh M.S., Shao Z.M., Hussain A., Clemmons D.R., Chen J.C., Roberts C.T., LeRoith D., Fontana J.A. Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells. Journal of Cellular Physiology 1993, 155:556-567.
42. Fontana J.A., Burrows-Mezu A., Clemmons D.R., LeRoith D. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 1991, 128:1115-1122.
43. Ren Z., Shin A., Cai Q., Shu X.O., Gao Y.T., Zheng W. IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Research: BCR 2007, 9:R2.
44. Wang H., Wang H., Shen W., Huang H., Hu L., Ramdas L., Zhou Y.H., Liao W.S.L., Fuller G.N., Zhang W. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Research 2003, 63:4315-4321.
45. Lee E.J., Mircean C., Shmulevich I., Wang H., Liu J., Niemistö A., Kavanagh J.J., Lee J.H., Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Molecular Cancer 2005, 4:7.